Business Wire

IRISYS

28.7.2020 12:02:09 CEST | Business Wire | Press release

Share
Irisys SafeCount Live Occupancy Monitoring Solution Automates Occupancy Compliance and Enables Social Distancing for Buildings and Rooms With One or Multiple Entrances

The COVID-19 pandemic has created an urgent need to accurately and efficiently manage occupancy regulations and enable social distancing in corporate workspaces, higher education buildings, retail stores, and manufacturing facilities. The Irisys SafeCount™ Live Occupancy Monitoring Solution helps businesses comply with social distancing and occupancy guidelines by anonymously counting people as they enter and exit buildings and rooms.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200728005318/en/

Suitable for buildings of all sizes, even those with multiple entrances and exits, SafeCount delivers live occupancy data with visual warnings and alerts when limits are approached or exceeded.

Built on the advanced Irisys Vector 4D people counting sensor, SafeCount features:

  • Easy, fast installation — Simple setup and configuration in less than 30 minutes.
  • Highly accurate — Better than 99 percent sensor accuracy that is unaffected by environmental conditions or large crowds.
  • Privacy protection — no personally identifiable information is captured by the system.
  • Staff detection — advanced functionality can exclude staff from occupancy count.
  • Standalone system, yet scalable — SafeCount works separately from existing IT networks and you can add the optional SafeCount Plus cloud platform for remote management and reporting.

“The Irisys SafeCount dashboard puts real-time occupancy data in the hands of attendants and managers while the historical reports provide an audit trail for social distancing compliance,” said Mike Slevin, director of sales at Irisys “Perhaps more importantly, SafeCount gives customers, employees, and visitors peace of mind that your company is protecting their health and safety.”

The SafeCount Plus cloud platform supports an unlimited number of buildings in different locations and time zones. Its advanced reporting enables managers to easily review, compare and analyze occupancy data to identify locations that are not complying with occupancy restrictions, allowing them to take action.

For more information on Irisys SafeCount Live Occupancy Monitoring, visit: https://www.irisys.net/products/safecount-occupancy-monitoring-solution .

About Irisys

Infrared Integrated Systems Ltd, generally called Irisys, is the largest global provider of people counting and real-time queue management solutions. The company’s technology is use by major organizations globally in sectors varying from retail, banks, transport to leisure facilities and public buildings. The systems give operators an unprecedented insight into their business, giving them the information they need to improve customer service, operational efficiency, and profitability. Companies often find opportunities for rapid improvements in their business, and a quick return on investment.

In 2012, Irisys became part of the Fluke Corporation , a worldwide leader in calibration and handheld test instruments. Fluke is world famous for the durability of its test tools and offers a range of tough electrical test tools, infrared thermometers, thermal imagers, and other devices designed for extreme field use.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

IQM Appoints Craig Ciesla, Former Illumina VP, as CTO; Inés de Vega Becomes Chief Scientist19.6.2026 09:00:00 CEST | Press release

Ciesla is a seasoned deep tech executive with more than 25 years of experience delivering products across industries — from startups to Fortune 500 companies. De Vega brings more than 20 years of experience advancing quantum technologies from fundamental research to intellectual property and industrial applications. IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointments of Dr. Craig Ciesla as Chief Technology Officer (CTO) and Dr. Inés de Vega as Chief Scientist, as she transitions from her role as Vice President of Quantum Solutions, deepening IQM´s leadership as the company prepares for its planned Nasdaq listing through a merger with Real Asset Acquisition Corp. (Nasdaq: RAAQ). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260619693929/en/ From left to right: Dr. Inés de Vega, Chief Scientist, and Dr. Craig Ciesla, Chief Technology Officer. Ciesla, an experienced d

Teijin Receives Approval for Additional Indications of XEOMIN® for Cervical Dystonia and Blepharospasm in Japan19.6.2026 09:00:00 CEST | Press release

Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business, and Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, jointly announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved the additional indications for XEOMIN® (incobotulinumtoxinA) for the treatment of cervical dystonia and blepharospasm. This approval represents the fourth and fifth indications for XEOMIN® authorized in Japan, alongside its existing approvals for the treatment of upper limb spasticity, lower limb spasticity and chronic sialorrhea. Cervical dystonia is a focal dystonia characterized by involuntary contractions of the neck muscles, resulting in abnormal or repetitive movements and postures.1 Blepharospasm is also a focal dystonia, characterized by excessive involuntary contractions of the muscles surrounding the eye.2 Both conditions significantly impact patients’ quality of life. The approval by MHLW is based on Phase III clinic

Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)19.6.2026 08:00:00 CEST | Press release

Incyte Biosciences Japan G.K. today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Minjuvi® (tafasitamab) in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). “This approval provides a new option for patients in Japan living with relapsed or refractory DLBCL, an aggressive disease with historically limited treatment options,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “We are committed to helping address critical unmet needs for patients and their families affected by this challenging cancer.” DLBCL is the most common subtype of non-Hodgkin lymphoma and is an aggressive malignancy of B lymphocytes. While many patients respond to initial therapy, outcomes remain poor for those with relapsed or refractory disease, particularly for patients who are not eligible for autologous stem cell transplant.1 The approval is based on results from the MOR208C203 Trial: L

Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training18.6.2026 19:07:00 CEST | Press release

New multi-sensor system captures heart rate, movement quality, stability and muscle load to provide a more complete view of performance under fatigue Amazfit, a leading global smart wearable brand owned by Zepp Health (NYSE: ZEPP), today announced Helio Strap Pro, a body-worn training system designed to help HYROX and hybrid athletes better understand how their bodies perform under load. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260618031434/en/ Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training Building on the screen-free Helio Strap, Helio Strap Pro adds a dedicated waist-mounted motion sensor that captures core-body movement and stability during training. Combined with upper-arm heart-rate sensing and compatible Amazfit smartwatches, the system provides a more complete picture of cardio effort, movement quality and muscle load than wrist-based tracking alone. Hel

HyperLight Announces $80 Million Series C to Accelerate TFLN Deployment for AI Infrastructure18.6.2026 17:30:00 CEST | Press release

HyperLight Corporation (“HyperLight”), a leader in thin-film lithium niobate (TFLN) photonics, today announced the closing of an $80 million Series C financing round led by MediaTek. The round includes participation from UMC Capital, Jabil, Foxconn, EDBI (arm of SG Growth Capital, the investment platform of the Singapore Economic Development Board and Enterprise Singapore), CDIB-TEN Capital, and Qatar Investment Authority (QIA), as well as strategic investors from leading silicon IC and networking companies. Existing investors Summit Partners, The Engine, Foothill Ventures, and Xora Innovation continue to actively support the company’s growth. The financing brings together companies across the AI infrastructure value chain — including silicon ICs, foundry manufacturing, electronics manufacturing services, networking, and global infrastructure investment — reflecting broad ecosystem support for scaling TFLN photonics into production. “This financing is about more than capital — it is ab

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye